vaayaa.com
Healthcare 1 min read

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

May 01, 2026

FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.

Read full article on FDA Press Releases →

Source: FDA Press Releases — US Government, Public Domain

More in Healthcare

What Pennsylvania’s AI chatbot lawsuit teaches us about the psychology behind medical trust The Conversation Health · 2 min World Cup creates perfect conditions for infectious diseases to spread – here are the biggest threats health experts are watching for The Conversation Health · 2 min FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose FDA Press Releases · 1 min Summer between high school graduation and college is a critical time for preventing risky behaviors – here’s how parents can play a key role The Conversation Health · 2 min